PHA-793887

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII MKS45S912B
EPA CompTox DTXSID50222134

Structure

InChI Key HUXYBQXJVXOMKX-UHFFFAOYSA-N
Smiles CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C
InChI
InChI=1S/C19H31N5O2/c1-12(2)10-15(25)20-17-14-11-24(19(3,4)16(14)21-22-17)18(26)13-6-8-23(5)9-7-13/h12-13H,6-11H2,1-5H3,(H2,20,21,22,25)

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H31N5O2
Molecular Weight 361.49
AlogP 2.31
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 4.0
Polar Surface Area 81.33
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 26.0

Bioactivity

Mechanism of Action Action Reference
Cyclin-dependent kinase inhibitor INHIBITOR PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase CMGC protein kinase group CMGC protein kinase CDK family CMGC protein kinase CDC2 subfamily
- 60 - - -
Enzyme Kinase Protein Kinase CMGC protein kinase group CMGC protein kinase CDK family CMGC protein kinase CDK5 subfamily
- 5 - - -
Enzyme Kinase Protein Kinase CMGC protein kinase group CMGC protein kinase CDK family CMGC protein kinase CDK7 subfamily
- 10 - - -
Enzyme Kinase Protein Kinase CMGC protein kinase group CMGC protein kinase CDK family CMGC protein kinase CDK9 subfamily
- 138 - - -
Enzyme Kinase Protein Kinase CMGC protein kinase group CMGC protein kinase GSK family
- 79 - - -
Enzyme Kinase Protein Kinase CMGC protein kinase group
- 10 - - -
Enzyme Kinase Protein kinase regulatory subunit
- 5 - - -
Other cytosolic protein
- 10 - - -
Assay Description Organism Bioactivity Reference
Inhibition of human CDK2/cyclin A expressed in Escherichia coli BL21 by scintillation proximity assay Homo sapiens 8.0 nM
Inhibition of CDK2/cyclin E by scintillation proximity assay None 8.0 nM
Inhibition of CDK5/p25 by scintillation proximity assay None 5.0 nM
Inhibition of CDK7/cyclin H by scintillation proximity assay None 10.0 nM
Inhibition of CDK1/cyclin B None 60.0 nM
Inhibition of CDK4/cyclin D1 by scintillation proximity assay None 62.0 nM
Inhibition of CDK9/cyclin T1 by scintillation proximity assay None 138.0 nM
Inhibition of GSK3-beta by scintillation proximity assay None 79.0 nM
Antiproliferative activity against human A2780 cells after 72 hrs by fluorescence assay Homo sapiens 90.0 nM
Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Homo sapiens 163.0 nM
Antiproliferative activity against human COLO205 cells after 72 hrs by SRB assay Homo sapiens 188.0 nM
Antiproliferative activity against human C-433 cells after 72 hrs by SRB assay Homo sapiens 285.0 nM
Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Homo sapiens 303.0 nM
Antiproliferative activity against human A375 cells after 72 hrs by SRB assay Homo sapiens 396.0 nM
Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay Homo sapiens 601.0 nM
Antitumor activity against human A2780 cells xenografted in BALB/c nu/nu mouse assessed as inhibition of tumor growth at 30 mg/kg, iv QD for 10 consecutive days measured every 3 days post last dose Homo sapiens 76.0 %
Antitumor activity against human HCT116 cells xenografted in BALB/c nu/nu mouse assessed as inhibition of tumor growth at 20 mg/kg, iv QD for 10 consecutive days measured every 3 days post last dose Homo sapiens 84.0 %
Antitumor activity against human BxPC3 cells xenografted in BALB/c nu/nu mouse assessed as inhibition of tumor growth at 20 mg/kg, iv QD for 10 consecutive days measured every 3 days post last dose Homo sapiens 84.0 %
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 444.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 98.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 8.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 135.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 8.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 218.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 7.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 10.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 3.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 29.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 12.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 264.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 864.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 103.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 65.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 175.0 nM
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. Homo sapiens 838.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -14.46 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 8.94 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 2.881 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.95 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.41 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.95 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.41 %

Cross References

Resources Reference
ChEBI 91371
ChEMBL CHEMBL1230607
DrugBank DB12686
FDA SRS MKS45S912B
PDB 889
PubChem 46191454
SureChEMBL SCHEMBL5110328
ZINC ZINC000052509437
CONTENTS